Compare Marriott International Inc (MAR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Marriott International Inc trades at $375.18 (market cap $96.87B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Marriott International Inc is far larger — about 99.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Marriott International Inc pays a 0.79% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MAR | MRVI | |
|---|---|---|
Market Cap | $96.87B | $972.90M |
Volume | 755,878 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $9.00 |
52-Week Low | $259.04 | $2.83 |
Typical Hold Time | 164 Days | 0 Days |
Enterprise Value | $114.19B | $1.08B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $371.82, up 0.68% today, near its resistance at $372. The stock shows bullish technical signals with strong moving averages, though the RSI indicates mild overbought conditions. Fundamentally, revenue grew to $26.19B in 2025 with a net income margin of 9.62%, but the P/E of 38.46 and P/B of 443.63 reflect premium valuation. Recent earnings beat expectations in Q1 and Q2 2026, and the company announced a quarterly dividend of $0.73 per share.
The outlook for MAR is positive, supported by robust travel demand and strategic initiatives like new technology partnerships. However, risks include high debt levels, with debt-to-asset ratio rising to 55.17% in 2024, and sensitivity to economic cycles. Analysts maintain a consensus price target of $388.93, suggesting moderate upside, but investors should weigh valuation concerns against growth prospects in the hospitality sector.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
